BioSpace News Archive

Larimar Therapeutics, Inc. (Nasdaq:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the company’s application for orphan drug designation for CTI-1601, a potential treatment for Friedreich’s ataxia (FA), a rare, progressive, multi-symptom genetic disease t

Expanded role of Ms. Stafford as Chairman reflects the Board’s confidence in her leadership of the Company and strategic direction Renowned pharmaceutical executive Robert Ingram retiring as Executive Chair and remaining a member of Board of Directors MORRISVILLE, N.C., July 28, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced an expanded role of Paula Brown Stafford, President and Chief Executive Officer (“CEO”) of Novan, to als

DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today the appointment of Bryan Laffitte , Ph.D., as Vice President, Biology. In his newly created role, Dr. Laffitte will be responsible for leading the company’s research and development

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2020 financial results on Tuesday, August 4, 2020 , after the close of US markets. Management will host a conference call on the same

Adastra Pharmaceuticals Inc. today announced it will present a corporate overview at the Private Healthcare Company Virtual Summer Symposium hosted by LifeSci Partners Aug. 4-5 . Adastra is a clinical-stage biotechnology company developing a potent, orally delivered kinase inhibitor that readily crosses the blood brain barrier and p

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted therapeutics for neurodegenerative diseases and neurodevelopmental disorders, today announces it has received a research grant of $440,000 from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through its Therapeutic Pipeline Program. The award will enable development of a novel in vitro model system of the e

Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personaliz

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced enrollment of its first patient in GRADIENT, a double-blind, placebo-controlled, Phase 3 trial of relacorilant in patients with Cushing’s syndrome caused by adrenal adenomas or hyperplasia. “We are

Aegea Biotechnologies, Inc. (“Aegea”) ( www.aegeabiotech.com ), a biotechnology company focused on the development and commercialization of next generation nucleic-acid diagnostic technologies, announces progress on the development of its Point-of-Care (“POC”) COVID-19 diagnostic test.

Agreement with Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited, a subsidiary of Lee’s Pharmaceutical Holdings Limited, provides license to IC 265 and IC 270, novel first-in-class therapies being developed for dry eye and allergic conjunctivitis, respectively, in China, a major growth market, and Southeast Asia [28-July-2020] IRVINE, Calif. and HONG KONG , July